Recherchemedicale.com
Tumeurs
Tumeurs par type histologique
Tumeurs épithéliales épidermoïdes et glandulaires
Carcinomes
Adénocarcinome
Cholangiocarcinome
Cholangiocarcinome : Questions médicales fréquentes
Diagnostic
5
Cholangiocarcinome
Biopsie
Imagerie par résonance magnétique
Marqueurs tumoraux
Tests de fonction hépatique
Cholangiocarcinome
Échographie
Cholangiocarcinome
Voies biliaires
Cholangiographie
Cholangiocarcinome
Obstruction biliaire
Jaunisse
Cholangiocarcinome
Symptômes
Symptômes
5
Cholangiocarcinome
Symptômes
Jaunisse
Fatigue
Cholangiocarcinome
Anémie
Jaunisse
Cholangiocarcinome
Peau
Nausées
Cholangiocarcinome
Troubles digestifs
Démangeaisons
Cholangiocarcinome
Bile
Prévention
5
Prévention
Cholangiocarcinome
Facteurs de risque
Produits chimiques
Cholangiocarcinome
Infections hépatiques
Tabagisme
Cholangiocarcinome
Facteurs de risque
Alimentation
Cholangiocarcinome
Maladies hépatiques
Vaccination
Cholangiocarcinome
Hépatite B
Traitements
5
Cholangiocarcinome
Chirurgie
Chimiothérapie
Chirurgie
Cholangiocarcinome
Cancer localisé
Chimiothérapie
Cholangiocarcinome
Récidive
Radiothérapie
Cholangiocarcinome
Symptômes
Essais cliniques
Cholangiocarcinome
Thérapies ciblées
Complications
5
Complications
Cholangiocarcinome
Obstruction biliaire
Obstruction biliaire
Cholangiocarcinome
Jaunisse
Infections
Cholangiocarcinome
Voies biliaires
Propagation
Cholangiocarcinome
Traitement complexe
Récidive
Cholangiocarcinome
Pronostic
Facteurs de risque
5
Facteurs de risque
Cholangiocarcinome
Hépatite
Âge
Cholangiocarcinome
Facteurs de risque
Maladies hépatiques
Cholangiocarcinome
Cirrhose
Infections parasitaires
Cholangiocarcinome
Clonorchis
Sexe
Cholangiocarcinome
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cholangiocarcinome : Questions médicales les plus fréquentes",
"headline": "Cholangiocarcinome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cholangiocarcinome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-01-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cholangiocarcinome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Adénocarcinome",
"url": "https://recherchemedicale.com/mesh/D000230",
"about": {
"@type": "MedicalCondition",
"name": "Adénocarcinome",
"code": {
"@type": "MedicalCode",
"code": "D000230",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.200.025"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeur de Klatskin",
"alternateName": "Klatskin Tumor",
"url": "https://recherchemedicale.com/mesh/D018285",
"about": {
"@type": "MedicalCondition",
"name": "Tumeur de Klatskin",
"code": {
"@type": "MedicalCode",
"code": "D018285",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.200.025.450.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Cholangiocarcinome",
"alternateName": "Cholangiocarcinoma",
"code": {
"@type": "MedicalCode",
"code": "D018281",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Shahid A Khan",
"url": "https://recherchemedicale.com/author/Shahid%20A%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Liver Unit, Division of Digestive Diseases, Imperial College London, London, UK."
}
},
{
"@type": "Person",
"name": "Gregory J Gores",
"url": "https://recherchemedicale.com/author/Gregory%20J%20Gores",
"affiliation": {
"@type": "Organization",
"name": "Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. gores.gregory@mayo.edu."
}
},
{
"@type": "Person",
"name": "Samantha Sarcognato",
"url": "https://recherchemedicale.com/author/Samantha%20Sarcognato",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy."
}
},
{
"@type": "Person",
"name": "Luca Fabris",
"url": "https://recherchemedicale.com/author/Luca%20Fabris",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Medicine - DMM, University of Padova, Padova, Italy."
}
},
{
"@type": "Person",
"name": "Massimiliano Cadamuro",
"url": "https://recherchemedicale.com/author/Massimiliano%20Cadamuro",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Medicine - DMM, University of Padova, Padova, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cholangiocarcinoma.",
"datePublished": "2024-05-10",
"url": "https://recherchemedicale.com/article/39448128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.suc.2024.04.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathology of Cholangiocarcinomas.",
"datePublished": "2022-12-26",
"url": "https://recherchemedicale.com/article/36661679",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol30010030"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunobiology of cholangiocarcinoma.",
"datePublished": "2023-05-16",
"url": "https://recherchemedicale.com/article/37201670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhep.2023.05.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "FGFR2 Inhibition in Cholangiocarcinoma.",
"datePublished": "2022-09-28",
"url": "https://recherchemedicale.com/article/36170665",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1146/annurev-med-042921-024707"
}
},
{
"@type": "ScholarlyArticle",
"name": "The multidisciplinary management of cholangiocarcinoma.",
"datePublished": "2022-11-16",
"url": "https://recherchemedicale.com/article/36382577",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cncr.34541"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://recherchemedicale.com/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://recherchemedicale.com/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"item": "https://recherchemedicale.com/mesh/D009375"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carcinomes",
"item": "https://recherchemedicale.com/mesh/D002277"
},
{
"@type": "ListItem",
"position": 6,
"name": "Adénocarcinome",
"item": "https://recherchemedicale.com/mesh/D000230"
},
{
"@type": "ListItem",
"position": 7,
"name": "Cholangiocarcinome",
"item": "https://recherchemedicale.com/mesh/D018281"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cholangiocarcinome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cholangiocarcinome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-22",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cholangiocarcinome",
"description": "Comment diagnostique-t-on un cholangiocarcinome ?\nQuels tests sanguins sont utilisés ?\nQuelle est l'importance de l'échographie ?\nPeut-on utiliser la cholangiographie ?\nQuels sont les signes d'alerte au diagnostic ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cholangiocarcinome",
"description": "Quels sont les symptômes courants du cholangiocarcinome ?\nLa fatigue est-elle un symptôme ?\nComment se manifeste la jaunisse ?\nY a-t-il des symptômes digestifs ?\nLes démangeaisons sont-elles fréquentes ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cholangiocarcinome",
"description": "Peut-on prévenir le cholangiocarcinome ?\nQuels facteurs de risque sont évitables ?\nLe tabagisme influence-t-il le risque ?\nL'alimentation joue-t-elle un rôle ?\nLes vaccinations sont-elles utiles ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cholangiocarcinome",
"description": "Quels sont les traitements disponibles ?\nLa chirurgie est-elle toujours possible ?\nQuel rôle joue la chimiothérapie ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements expérimentaux ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cholangiocarcinome",
"description": "Quelles sont les complications possibles ?\nComment l'obstruction biliaire se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nLe cancer peut-il se propager ?\nQuelles sont les conséquences de la récidive ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cholangiocarcinome",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes maladies hépatiques augmentent-elles le risque ?\nY a-t-il un lien avec des infections parasitaires ?\nLe sexe influence-t-il le risque ?",
"url": "https://recherchemedicale.com/mesh/D018281#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un cholangiocarcinome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie (IRM, CT) et la biopsie des tissus biliaires."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'échographie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie aide à visualiser les voies biliaires et détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la cholangiographie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la cholangiographie permet de visualiser les voies biliaires et d'identifier les obstructions."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'alerte au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent jaunisse, douleurs abdominales et démangeaisons cutanées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du cholangiocarcinome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, douleurs abdominales, perte de poids et démangeaisons."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être due à la maladie ou à l'anémie."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la jaunisse ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La jaunisse se manifeste par une coloration jaune de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes digestifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements et troubles digestifs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les démangeaisons sont-elles fréquentes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les démangeaisons cutanées sont un symptôme courant lié à l'accumulation de bile."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le cholangiocarcinome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évitables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition à des produits chimiques toxiques et traiter les infections hépatiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers, y compris le cholangiocarcinome."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais son impact direct est incertain."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vacciner contre l'hépatite B peut réduire le risque de cancer du foie et des voies biliaires."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la chirurgie est possible si le cancer est localisé et opérable."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la chimiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est utilisée pour réduire la taille des tumeurs ou traiter les récidives."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut soulager les symptômes et est souvent utilisée en complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques testent de nouveaux médicaments et thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'obstruction biliaire, l'infection et la propagation du cancer."
}
},
{
"@type": "Question",
"name": "Comment l'obstruction biliaire se manifeste-t-elle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par une jaunisse, des douleurs abdominales et des démangeaisons."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires."
}
},
{
"@type": "Question",
"name": "Le cancer peut-il se propager ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le cholangiocarcinome peut se propager à d'autres organes, rendant le traitement plus complexe."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences de la récidive ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La récidive peut nécessiter des traitements supplémentaires et affecter le pronostic."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hépatite, la cirrhose, et l'exposition à des produits chimiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 65 ans."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec des infections parasitaires ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections parasitaires, comme celles causées par le clonorchis, augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes sont généralement plus à risque que les femmes pour le cholangiocarcinome."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/01/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Liver Unit, Division of Digestive Diseases, Imperial College London, London, UK.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. gores.gregory@mayo.edu.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular Medicine - DMM, University of Padova, Padova, Italy.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular Medicine - DMM, University of Padova, Padova, Italy.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Department of Medicine - DIMED, University of Padova, Padova, Italy.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Surgery, The Ohio State University, 320 W. 10th Avenue, M-260 Starling Loving Hall, Columbus, OH 43210, USA.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Publications dans "Cholangiocarcinome" :
3 publications dans cette catégorie
Affiliations :
Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Trust Surrey and London, London, United Kingdom.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
4th Surgery Unit, Azienda ULSS2 Marca Trevigiana, Treviso, Italy.
Department of Surgery, Oncology and Gastroenterology - DISCOG, University of Padova, Padova, Italy.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, NY 11201, USA.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Section of Gastroenterology, Department of Medical Sciences, University of Foggia, 71122 Foggia, Italy.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Section of Gastroenterology, Department of Medical Sciences, University of Foggia, 71122 Foggia, Italy.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
Department of Surgery, Johns Hopkins University, 600 N. Wolfe St, Tower 110 Baltimore, MD 21287, USA. Electronic address: aslam.ejaz@osumc.edu.
Publications dans "Cholangiocarcinome" :
2 publications dans cette catégorie
Affiliations :
UCLA, Division of Hematology and Oncology, Los Angeles, California, USA. ssadeghi@mednet.ucla.edu.
Publications dans "Cholangiocarcinome" :
Management of intrahepatic cholangiocarcinoma relies on a thorough understanding of the tumor's location and proximity to critical vasculobiliary structures. Mid-common bile duct tumors may require he...
Cholangiocarcinomas (CCA) are heterogeneous tumors that arise from epithelial cells of the biliary tract. They represent the second primary liver malignancy, after hepatocellular carcinoma. Recent epi...
Recent literature has significantly advanced our knowledge and understanding of the tumour immune microenvironment of cholangiocarcinoma. Detailed characterisation of the immune landscape has defined ...
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical...
Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. Howe...
Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have been the only trea...
Cholangiocarcinoma (CCA) is the most common primary biliary malignancy with an adverse prognosis. Although its incidence is relatively low, early diagnosis is difficult due to the lack of specific sym...
Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the increased energy demands required for rapid proliferation, invasion, and metastasis. Indeed, many tumour cells acqui...
Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biol...
Integrative genomic analysis with functional validation uncovered biological perturbations downstream of driver events including DPCR1 , RBM47 mutations, SH3BGRL2 copy number alterations, and FGFR2 fu...
We characterized the proteogenomic landscape of 217 CCAs with 197 paired normal adjacent tissues and identified their subtypes and potential therapeutic targets. The multiomics analyses with other dat...
Lymphoepithelioma-like intrahepatic cholangiocarcinoma (LEICC) has been recently introduced as a genetically distinct of intrahepatic cholangiocarcinoma (ICC). We aimed to investigate whether LEICC ha...
Five hundred and sixty-seven consecutive patients who underwent surgical resection or liver transplantation for ICC between 2014 and 2021 were retrospectively identified. Among them, 30 patients with ...
LEICCs showed significantly higher frequencies of a non-rim arterial phase hyperenhancement (APHE), washout on post-arterial images and a smooth margin, as well as less frequencies of perilesional enh...
Compared with classical ICCs, LEICCs do have distinct radiological characteristics. A smooth margin, non-rim APHE, washout on post-arterial images, absent perilesional enhancement and absent liver cap...